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Abstract
Background—Evidence regarding the consumption of soy foods and isoflavones in relation to 
risk of type 2 diabetes (T2D) is scarce.
Objective—Our study was to evaluate the association between soy food and isoflavone 
consumption and risk of T2D in US men and women.
Methods—We followed 63,115 women in the Nurses’ Health Study (1998-2012), 79,061 women 
in the Nurses’ Health Study II (1999-2013), and 21,281 men in the Health Professionals Follow-
Up Study (2002-2010). Diet was assessed by a validated food-frequency questionnaire, and was 
updated every 4 y. Self-reports of incident T2D was confirmed by a validated supplementary 
questionnaire.
Results—During 1,966,321 person-years of follow-up, 9,185 incident T2D cases were 
documented. After multivariate adjustment for covariates, consumption of soy foods (tofu and soy 
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milk) was not associated with a lower T2D risk. Compared to non-consumers of soy foods, the 
hazard ratio (HR) was 1.00 (95% CI: 0.93, 1.07) for <1 serving/week, and 0.93 (95% CI: 0.83, 
1.03) for ≥1 serving/week of soy foods (P for trend = 0.14). In contrast, intake of total isoflavones 
was inversely associated with T2D risk. Comparing extreme quintiles of isoflavones, the HR was 
0.89 (95% CI: 0.83, 0.96; P for trend = 0.009). Inverse associations were also found for 
consumption of major individual isoflavones, including daidzein and genistein, with risk of T2D.
Conclusions—Intake of isoflavones was associated with a modestly lower T2D risk in US men 
and women who typically consumed low to moderate amounts of soy foods. These findings 
warrant replications in other populations with similar soy intake levels.
Keywords
isoflavones; soy food; type 2 diabetes
INTRODUCTION
Type 2 diabetes (T2D) is a chronic disease with increasing prevalence worldwide. The total 
number of people with diabetes, globally, is 382 million in 2013 and is estimated to reach 
592 million by the year 2035.1 Identification of modifiable lifestyle and dietary risk factors 
for T2D prevention is of high priority. Specific components of plant-based foods have been 
shown to exert significant health benefits.2 For example, consumption of coffee and 
blueberries has been associated with a lower risk of T2D in Western populations, and certain 
flavonoid subclasses, such as phenolic acids and anthocyanins, may contribute to the health 
benefits of these foods.3-5 In contrast, evidence regarding other plant-based foods, such as 
soy foods, that are regarded as healthful but not intrinsic to the traditional Western diet is 
sparse.
Soy foods are uniquely rich in isoflavones compared to other foods.6 Isoflavones are in the 
family of flavonoids that share a common chemical structure of 2 aromatic rings bound 
together by 3 carbon atoms that form an oxygenated heterocycle. 7 Depending on the 
position of hydroxyl groups in replacement of hydrogen atoms, isoflavones can be 
categorized into three subtypes: daidzein, genistein, and glycitein. The contents of these 
isoflavones are much higher in soy foods, such as tofu and soy milk, than other foods that do 
not contain soy ingredients, with daidzein and genistein contents higher than glycitein in soy 
foods. Isoflavones have a structure analogous to 17-β-estradiol and have weak estrogen-like 
effects by binding to estrogen receptors.8 Because the structural conformation of genistein 
resembles estradiol the most, genistein has the strongest binding capacity to estrogen 
receptor. 9 Daidzein and genistein could be converted by gut bacteria into metabolites such 
as equol, desmethylangolensin (DMA), dihydrogenistein (DHGE), and dihydrodaidzein 
(DHDE). Several clinical trials have been conducted to examine the effects of soy foods and 
isoflavones on glucose homeostasis, and results have suggested that soy foods and soy-rich 
diets may lower blood glucose.10-13 However, these clinical trials are limited by small 
sample sizes and short durations of follow-up. Few prospective studies have been conducted 
to evaluate the associations between intakes of soy foods and isoflavones and T2D risk in 
Western populations who consume low to moderate amounts of soy foods 14.
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We conducted a prospective analysis of data collected in 3 large US cohorts, the Nurses’ 
Health Study (NHS), the NHSII, and the Health Professionals Follow-Up Study (HPFS) to 
examine the associations between consumption of soy food and isoflavones and risk of T2D.
METHODS
Study population
The NHS began in 1976, when 121,700 female registered nurses aged 30-55 y residing in 11 
states were enrolled and completed a baseline questionnaire about their lifestyle and medical 
history. The NHSII was established in 1989 and consisted of 116,671 younger female 
registered nurses aged 25-42 y at baseline. These women responded to a baseline 
questionnaire similar to the one used in NHS. The HPFS was initiated in 1986, and was 
composed of 51,529 male dentists, pharmacists, veterinarians, optometrists, osteopathic 
physicians, and podiatrists aged 40-75 y at baseline. The male participants returned a 
baseline questionnaire about their medical history, lifestyle, and usual diet. In all three 
cohorts, questionnaires were administered at baseline and biennially thereafter to update 
information on lifestyle factors and the occurrence of chronic diseases.
For the current analysis, we excluded participants who reported diagnosed diabetes 
(including type 1 and type 2 diabetes, and gestational diabetes), cardiovascular disease 
(CVD), or cancer at baseline (1998 for the NHS, 1999 for the NHSII, and 2002 for the 
HPFS). We further excluded participants with missing soy or isoflavone consumption at 
baseline (when soy milk was first included) and those who left more than 70 food items 
blank or had daily energy intakes <600 or > 3500 kcal for women and <800 or >4200 kcal 
for men. Overall, 21,665 NHS participants, 8,537 NHSII participants, and 16,120 HPFS 
participants were excluded from the analysis. After these exclusions, data from 63,115 NHS 
participants, 79,061 NHSII participants, and 21,281 HPFS participants were available for the 
analysis. The study protocol was approved by the institutional review boards of Brigham and 
Women’s Hospital and Harvard School of Public Health. The completion of the self-
administered questionnaire was considered to imply informed consent.
Assessment of isoflavone and soy food consumption
In 1984, a 116-item food frequency questionnaire (FFQ) was administered to the NHS 
participants to obtain information on usual intake of food and beverages. Since 1986, an 
expanded FFQ has been administered every 4 years to update diet. Using a similar FFQ, 
dietary data were collected every four years from the NHSII participants since 1991 and 
from the HPFS participants since 1986. In all FFQs, participants were asked how often 
(from “never or less than once per month” to “6 or more times per day”) on average they 
consumed each food item of a standard portion size during the previous year. Major soy 
foods, i.e., tofu and soy milk, have been simultaneously included on the FFQs since 1998 in 
the NHS, 1999 in the NHSII, and 2002 in the HPFS. We therefore used these years as study 
baselines. Intake of isoflavones and other nutrients was calculated by multiplying the 
consumption frequency of each food item by the nutrient content of the specified portion and 
summing the contributions from all food items. We calculated consumption of genistein, 
daidzein, and glycitein from foods. Isoflavones from supplements were not included in these 
Ding et al. Page 3
Eur J Clin Nutr. Author manuscript; available in PMC 2017 January 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
calculations. The food composition of isoflavones was created primarily from the USDA 
Database for the Isoflavone Content of Selected Foods, Release 2.0 6. Consumption of total 
soy food was calculated as the sum of the consumption of tofu and soy milk in servings/day. 
The validity and reproducibility of the FFQ has been described in detail elsewhere.15-18 The 
correlation coefficient for tofu consumption assessed by FFQs and diet records was 0.56.15
Assessment of covariates
In the biennial follow-up questionnaires, we collected and updated information on age, body 
weight and height, smoking status, physical activity, medication use, family history of 
diabetes, and disease status, including hypertension, hypercholesterolemia, CVD, and 
cancer. We also ascertained data on menopausal status and postmenopausal hormone use in 
both NHS and NHSII, as well as oral contraceptive use in NHSII. An overall measurement 
of diet quality was derived using the alternate Healthy Eating Index (aHEI) score excluding 
tofu and soy milk.
Assessment of type 2 diabetes (T2D)
Participants with self-reported incident T2D were mailed a validated supplementary 
questionnaire regarding symptoms, diagnostic tests, and hypoglycemic therapy to confirm 
the diagnosis of diabetes. Cases were ascertained using the American Diabetes Association 
criteria:19 1) one or more classic symptoms (excessive thirst, polyuria, weight loss, hunger) 
and fasting plasma glucose concentrations ≥7.0 mmol/L or random plasma glucose 
concentrations ≥11.1 mmol/L; 2) ≥2 elevated plasma glucose concentrations on different 
occasions (fasting concentrations ≥7.0 mmol/L, random plasma glucose concentrations 
≥11.1 mmol/L, and/or concentrations of ≥11.1 mmol/L after ≥2 h shown by oral-glucose-
tolerance testing) in the absence of symptoms; or 3) treatment with hypoglycemic 
medication (insulin or oral hypoglycemic agent). In addition, hemoglobin A1c≥6.5% was 
added to the diagnosis criteria since 2010. Only cases confirmed by the supplemental 
questionnaires were included in our analysis.
The validity of the supplementary questionnaire for the diagnosis of diabetes has been 
documented previously. In a validation study, of the 62 cases in the NHS and 59 cases in 
HPFS who were confirmed by the supplemental questionnaire, 61 (98%) and 57 (97%) were 
reconfirmed by reviewing medical records.20,21
Statistical analysis
We calculated person-time for each individual from the date of the return of the baseline 
questionnaire to the date of diagnosis of T2D, death, or the end of follow-up (30 June 2012 
for the NHS, 30 June 2013 for the NHSII, and 31 January 2010 for the HPFS), whichever 
came first. We used cumulative averages of soy food or isoflavone consumption to reflect 
long-term dietary habits. We stopped updating diet after incident cancer or CVD as these 
diseases may result in changes of diet that might confound the association between soy 
foods and risk of T2D. In addition, to minimize missing values during follow-up, we 
replaced missing soy food/isoflavone intakes during follow-up with valid values in the 
previous cycle. We used Cox proportional hazards regression models to examine the 
associations between soy foods and isoflavone consumption (quintiles) and risk of T2D. The 
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regression models included calendar time in 2-y intervals as the time scale, and were 
stratified by age in years. In multivariable analysis, we further adjusted for race (Causation, 
African American, Asian, and others), family history of T2D (yes, no), baseline disease 
status (hypertension and hypercholesterolemia), BMI (<20.9, 21-22.9, 23-24.9, 25-29.9, 
30-34.9, ≥35 kg/m2), physical activity (quintiles, met-hr/week), aHEI score (in quintiles), 
total energy intake (quintiles), and smoking status (never smoked, past smoker, currently 
smoked 1-14 cigarettes/d, and currently smoked >14 cigarettes/d). We additionally adjusted 
for menopausal status (yes, no), and postmenopausal hormone use (yes, no) in women. Test 
for linear trend was conducted by assigning the median value of exposure in each category 
to that category and treating the median value as a continuous variable in the regression 
model, with P < 0.05 denoting a significant association.
Analyses were performed separately in each cohort first. The pooled hazard ratios (HRs) 
were estimated by a stratified Cox model, which allowed baseline hazard to be different 
across the three cohorts while gave common effect estimates of the covariates. We examined 
potential effect modifications by BMI, age, and aHEI score for both men and women, and 
menopausal status and postmenopausal hormone use for women. Meta-regressions were 
used to test for potential interactions, with P value <0.05 denoting effect modification. The 
tests for interaction were conducted in analyses within individual cohorts as well as in 
analyses based on pooled data from all three cohorts. Previous studies showed that coffee 
intake also contributes to total isoflavone intake 22 and was associated with a lower T2D risk 
in these cohorts.5 To examine whether the association of isoflavones with diabetes risk may 
be due to coffee intake, we further calculated coffee-adjusted residuals of isoflavones using 
generalized equation estimation (GEE), and conducted a sensitivity analysis by using these 
residuals as the main exposure. All statistical tests were 2-sided and performed using SAS 
version 9.3 (SAS Institute Inc.). The meta-analysis was performed using STATA, version 9.2 
(StataCorp).
RESULTS
Baseline characteristics according to soy food consumption
Baseline characteristics of the participants in each cohort according to soy food consumption 
are shown in Table 1. Most of the participants were non-consumers of soy foods at baseline 
in the three cohorts. Soy food consumers had a higher aHEI score, higher consumption of 
fruit, vegetables, and fish, lower consumption of meat and soda (including sugar-sweetened 
beverages), and were more physically active than non-consumers.
The association of soy foods with risk of T2D
In the age-adjusted model, soy food consumption was inversely associated with risk of T2D. 
After multivariate adjustment, the association was attenuated and soy food consumption was 
non-significantly associated with a lower risk of T2D (Table 2). Compared with those who 
did not consume soy foods, the HR (95% CI) was 1.00 (0.93, 1.07) for those consuming < 1 
serving/week of soy foods, and 0.93 (0.83, 1.03; P = 0.14) for those consuming ≥1 serving/
week of soy foods in the pooled analysis. We further examined the association separately 
with tofu and soy milk intake. Compared with non-consumers, the HR was 1.00 (95% CI: 
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0.93, 1.08) for those consuming < 1 serving/week of tofu, and 0.93 (95% CI: 0.84, 1.04) for 
those consuming ≥1 serving/week of tofu. For soy milk, compared with non-consumers, the 
HR was 0.92 (95% CI: 0.83, 1.02) for soy milk consumers. No significant associations of 
total soy foods, tofu, and soy milk with risk of T2D were found in the NHS, NHSII, and 
HPFS cohorts, and the associations did not vary significantly across the three cohorts (all P 
values for heterogeneity >0.30).
The association of isoflavone consumption with risk of T2D
Total isoflavone consumption was significantly, inversely associated with risk of T2D (Table 
3). As compared with the lowest quintile of isoflavones consumption, the HRs (95% CIs) 
were 0.89 (0.83, 0.96) for highest quintiles in the pooled analysis (P for trend = 0.009). We 
further evaluated individual isoflavones with meaningful intake levels in our cohorts (Table 
4). For daidzein, the HR (95% CI) was 0.87 (0.81, 0.94) comparing extreme quintiles (P for 
trend = 0.0003). For genistein, the HR (95% CI) was 0.91 (0.85, 0.98) for the same 
comparison (P for trend = 0.02).
Of note, on average, regular soy food consumers (≥1 serving/week) had higher isoflavone 
intake levels than participants in the highest quintile of total isoflavones, but the associations 
for soy food intake were not significant, suggesting that the association for isoflavones may 
not be linear at relatively high intake level. However, when we further examined the dose-
response relationship between isoflavone intake and risk of T2D using spline regression, we 
did not observe a clear non-linear association (P for non-linearity: 0.76; P for trend = 0.02; 
Supplemental figure 1).
Stratified analysis
We conducted analyses stratified by menopausal status (premenopausal vs postmenopausal; 
women only), BMI (<30 kg/m2 vs ≥30 kg/m2), age (<60 y vs ≥60 y), and aHEI score (< 
median vs ≥ median), and no significant interactions were found between soy food and risk 
of T2D: P values for interaction were 0.20 for menopausal status, 0.78 for BMI, 0.34 for 
age, and 0.52 for aHEI score (Supplemental Table 1). No significant interactions were found 
between isoflavones consumption and these factors in relation to T2D risk (Supplemental 
Table 2). We further tested effect modification by postmenopausal hormone use on the 
associations between consumptions of soy food and isoflavones and risk of T2D among 
postmenopausal women, but no significant effect modification was found. We performed 
further analyses restricted within postmenopausal women who were never users of hormone 
therapy and within women who were never users of soy supplements. The associations 
between intakes of soy foods and isoflavones and risk of T2D did not change substantially.
Sensitivity analysis
As coffee was one of the food sources of isoflavones consumption,22 we conducted 
sensitivity analysis using coffee-adjusted residuals of isoflavones consumption. Similar to 
the results of isoflavones, inverse associations of residual consumption of isoflavones, 
daidzein, and genistein with risk of T2D were found (Supplemental table 3). As soy food 
consumption was associated with a healthy lifestyle, we further repeated our analysis on the 
association of soy food and isoflavones with risk of T2D using propensity score analysis. 
Ding et al. Page 6
Eur J Clin Nutr. Author manuscript; available in PMC 2017 January 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The results did not change significantly comparing with the main analysis (Supplemental 
table 4, 5). We repeated our analysis using stratified Cox model, and the associations of soy 
food and isoflavones with risk of T2D did not change significantly.
DISCUSSION
In three large US cohorts of men and women, we found that isoflavone consumption was 
modestly associated with a lower risk of T2D, whereas the two major soy foods, i.e., tofu 
and soy milk, were not associated with T2D risk. These associations were independent of 
established and potential lifestyle and dietary risk factors of T2D.
The association of soy foods and isoflavones with risk of T2D has been investigated 
primarily among Asian populations who have much higher intake levels compared with 
Western populations, and the results have been largely mixed. Villegas et al. found that 
higher intakes of soybean and soy milk were significantly associated with a lower T2D 
incidence in the Shanghai Women’s Health Study.23 In the Singapore Chinese Health Study, 
Mueller et al. further documented that intakes of unsweetened soy products (servings/week), 
but not sugar-sweetened soy foods, were associated with a lower T2D risk.24 However, a 
Japanese study found that intake of total soy foods (gram/day) with various soy protein 
densities was not associated with T2D risk,25 whereas intake of total soy foods (gram/day) 
was associated with a higher T2D risk in a multi-ethnic population living in Hawaii.26 
Lastly, no association between total isoflavone intake and risk of T2D was found in the 
EPIC-InterAct Study.14 The sources of heterogeneity in these findings are unclear, although 
study participant characteristics, including genetics, total energy intake, different exclusion 
criteria, various cooking methods, types of soy products, and measurement error in soy food 
or isoflavone assessment may partially explain the mixed results. In the current analysis, we 
evaluated both major soy foods and isoflavones in relation to T2D risk and found the 
associations did not vary significantly across three cohorts of men and women. We found 
that isoflavones rather than soy foods were associated with a lower risk of T2D and the 
reason might be that the isoflavones contents and other dietary constitutions of soy food 
differed across regions.
In contrast to the paucity of evidence from long-term prospective observational studies, data 
from short-term clinical trials that examined the effects of soy foods or isoflavones on 
diabetes risk factors were abundant, and results were mixed. In a comprehensive meta-
analysis of randomized controlled trials, supplementation of soy foods or isoflavones did not 
significantly lower fasting glucose or insulin levels, although a subgroup analysis showed 
that whole soy foods might reduce fasting glucose.11 In another meta-analysis that focused 
on premenopausal and postmenopausal non-Asian women who did not take hormone 
replacement therapy, isoflavone supplementation significantly lowered fasting insulin and 
HOMA-IR levels, although no effects were observed on fasting glucose levels.10 In addition, 
soy products improved blood lipid profiles among diabetes patients, although the effects on 
glucose metabolism parameters were not substantiated.12
Isoflavones have a structure analogous to 17-β-estradiol, which enables isoflavones bind to 
estrogen receptors β with 103-104 less potency than estradiol.8 Isoflavones exert either 
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estrogenic or anti-estrogenic effect depending on the concentration of serum estradiol. 
Isoflavones exert estrogen-like effects when the concentration of endogenous estrogen is 
low, otherwise, isoflavones might have anti-estrogenic effect. 27 Isoflavones also activate 
nuclear receptors including peroxisome-proliferator activated receptors (PPAR) α , PPAR γ, 
sterol regulated element binding protein, and liver X binding receptor to regulate lipid and 
glucose metabolism.28-30 Isoflavones have been shown to improve hyperglycemia, glucose 
tolerance, and circulating insulin concentrations.31 Isoflavones also stimulate the 
phosphorylation of AMP-activated protein kinase and acetyl-CoA carboxylase to increase 
glucose uptake and fatty acid oxidation.32 Estrogen increases insulin sensitivity in the liver, 
promotes pancreas β cell proliferation and differentiation, modulates appetite and energy 
expenditure by regulating the expression of leptin and ghrelin, effects glucose disposal in 
muscle by upregulating expression of glucose transporter 4 and proteins involving the 
insulin signaling pathway,33 and inhibits lipogenesis in adipose tissue by inhibiting the 
activity of lipoprotein lipase.34 Whether isoflavones have those effects analogous to estrogen 
is speculated and needs further investigation.
Our study has several strengths. First, the analysis was based on three well-characterized 
large cohorts with detailed measurements of diet and lifestyle. Second, consumption of 
isoflavones and soy products was assessed every 4 years during the follow-up. The repeated 
measurements not only reduce measurement error but also represent long-term dietary 
habits. Third, the aHEI score was used to adjust for confounding of the overall diet quality. 
We also controlled for a wide range of lifestyle factors in the analysis. Our study also has 
several limitations. First, although we used the comprehensive USDA food composition 
database of isoflavones to derive isoflavone intake and included major soy foods in the 
current analysis, measurement error may still exist and may attenuate the true associations 
towards the null due to the longitudinal study design. Second, the low consumption levels of 
soy products in our cohorts (90% of participants were non-consumers), typically seen among 
Western populations, limited the statistical power for the analysis of soy food. Third, 
residual confounding by lifestyle factors (e.g., dietary factors, physical activity, and 
smoking) may still exist due to model-misspecification and measurement error of potential 
confounders. Last, our study was conducted primarily among white health professionals, and 
thus the results may not be generalizable to other populations.
In conclusion, our analysis showed that consumption of isoflavones, but not tofu or soy 
milk, was associated with a modest reduction in risk of T2D in three large cohorts of U.S. 
men and women. Further studies are needed to replicate these observations in other 
populations, especially those with similar isoflavone intake levels.
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